In Silico Genesis signed up a Confidential Disclosure Agreement with Imanova, a spin-off company from GlaxoSmithKline (GSK), in April 2015. This CDA was originally signed by the CEO of Imanova on the 19th of April 2013, following a mutual interest identified in the area of CNS, whilst both companies attending One Nucleus CNS Leadership Seminar series in London on the 11th of February 2013.
Since then, Imanova and In Silico Genesis have both been selected to represent the strengths of British companies on the UK Trade and Investment CNS Trade Mission to British Embassy Seoul and British Embassy Tokyo, in the first week of November 2014. I was very impressed by the quality of the work presented by Imanova, and more so by his warmth and genuine respect which he showed to the people of South Korea and of Japan at the Embassies.
I had the pleasure of introducing my father to the CEO of Imanova at British Embassy Seoul. Then, I was deeply touched by how he opened his seminar at British Embassy Tokyo, sharing with the audience openly what Japan really meant to him and his daughter. I returned my signed copy of the original CDA bearing his signature, to the CEO of Imanova on the 19th of April, 2015. He is a hard-working CEO and believes in what Imanova can do to help people.
In Silico Genesis Ltd 
Leave a Reply